Show Summary Details
Page of

Gout and Crystal Arthropathies 

Gout and Crystal Arthropathies
Gout and Crystal Arthropathies

Lorna Clarson

and Edward Roddy

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 June 2022

Gout was first described by Hippocrates in the 5th century BC, as the ‘arthritis of the rich’, although archaeologists identified deposits of uric acid in the joints of mummified Egyptians dating back approximately 4,000 years. It was not until the 1800s that Sir Alfred Garrod differentiated gouty arthritis using the presence of serum hyperuricaemia and later suggested that hyperuricaemia could be controlled by limiting dietary intake of purines. Salicylates were used as uricosurics in the 1800s but were later replaced by other drugs. These were superseded by allopurinol in the 1960s, with the only widely available alternative to allopurinol introduced in 2005. Work continues with uricase treatments and interleukin receptor antagonists but these are not yet in common usage. Deposition of calcium pyrophosphate crystals is a common age-related phenomenon. The papers in this chapter report findings which made a substantial contribution to either the understanding or management of crystal arthropathies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.